Illumina stock skidded Tuesday after China signaled it would ban the company from importing its gene-mapping products.

Throughout the last three months, 7 analysts have evaluated Illumina (NASDAQ:ILMN), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of ...

China accounts for roughly 7% of Illumina’s total annual revenue, or about $300 million, though it has continued to decline in that market in recent quarters. Puneet Souda, a research analyst ...